Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype

Le résumé fourni par la source

RATIONALE: Cutaneous breast cancer metastasis carries poor prognosis. Phenotypic conversion to a triple-negative subtype presents therapeutic challenges. Re-biopsy is crucial. PATIENT CONCERNS: A 53-year-old female underwent right modified radical mastectomy for HER2-positive invasive breast carcinoma in September 2023, and developed pruritic, erythematous nodules on the right chest wall, axilla, and back 9 months later. DIAGNOSES: Histopathology revealed poorly differentiated dermal carcinoma. The primary tumor was ypT2N3aMx with 23/23 positive nodes, grade 3. IHC showed ER(-), PR(-), HER2 (3+), and Ki-67 (~40%). In October 2023, a supraclavicular lymph node biopsy revealed HER2 IHC 0, representing the first evidence of phenotypic conversion. In July 2024, biopsy of the cutaneous metastatic lesion confirmed HER2 IHC 0 (no membrane staining), ER(-), PR(-), and Ki-67 (~60%+), consistent with a persistent triple-negative phenotype. INTERVENTIONS: Treatment was switched to gemcitabine plus cisplatin combined with envafolimab (a PD-L1 inhibitor). Prior to initiation, PD-L1 IHC (SP263, Ventana) revealed TC 0%, IC+ <1%, and ICP ~10%. Six cycles were administered between August and November 2024. In January 2025, new lesions with ER 20% positivity emerged, and the regimen was adjusted to vinorelbine plus bevacizumab combined with envafolimab. OUTCOMES: The patient completed 6 cycles of gemcitabine plus cisplatin combined with envafolimab. Course was uneventful, with isolated grade 3 neutropenia (0.71 × 10^9/L) in October 2024. In January 2025, new cutaneous lesions emerged, prompting biopsy and regimen change. As of April 2025, the patient remained on active treatment with stable disease status. LESSONS: This case underlines re-biopsy importance. Conversion to a triple-negative phenotype necessitates complete change in systemic therapy. Phenotypic conversion may first manifest in lymph node metastases before becoming clinically evident in cutaneous lesions.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.